Polycythemia vera historical perspective: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia vera}} | {{Polycythemia vera}} | ||
{{CMG}}{{AE}}{{MJK}} | {{CMG}}{{AE}}{{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
In 2005, a mutation in the ''[[JAK2]]'' kinase (V617F) was found in multiple patients with myeloprolifrative neoplasm (including polycythemia vera) by different researchers.<ref name="pmid24069563">{{cite journal| author=Gäbler K, Behrmann I, Haan C| title=JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. | journal=JAKSTAT | year= 2013 | volume= 2 | issue= 3 | pages= e25025 | pmid=24069563 | doi=10.4161/jkst.25025 | pmc=PMC3772115 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24069563 }} </ref> | In 2005, a mutation in the ''[[JAK2]]'' kinase (V617F) was found in multiple patients with myeloprolifrative neoplasm (including polycythemia vera) by different researchers.<ref name="pmid24069563">{{cite journal| author=Gäbler K, Behrmann I, Haan C| title=JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. | journal=JAKSTAT | year= 2013 | volume= 2 | issue= 3 | pages= e25025 | pmid=24069563 | doi=10.4161/jkst.25025 | pmc=PMC3772115 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24069563 }} </ref> | ||
Revision as of 21:12, 20 January 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera historical perspective On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera historical perspective |
|
Risk calculators and risk factors for Polycythemia vera historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
In 2005, a mutation in the JAK2 kinase (V617F) was found in multiple patients with myeloprolifrative neoplasm (including polycythemia vera) by different researchers.[1]
Historical Perspective
- In 1892, Louis Henry Vaquez first described polycythemia vera as a disorder of red blood cells.[2]
- In 1903, Sir William Olser reinforced the concept of polycythemia vera.[2]
- In 1953, William Dameshek described myeloproliferative neoplasms as a group of disorders including polycythemia vera, essential thrombocythemia, and myelofibrosis.[2]
- In 2005, multiple groups including those led by William Vainchenker, Ross Levine, Robert Kralovics, and Tony Green first described the JAK2 V617F mutation in polycythemia vera.[2]
- In 2005, a mutation in the JAK2 kinase (V617F) was found in multiple patients with myeloprolifrative neoplasm (including polycythemia vera) by different researchers.[1]
References
- ↑ 1.0 1.1 Gäbler K, Behrmann I, Haan C (2013). "JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms". JAKSTAT. 2 (3): e25025. doi:10.4161/jkst.25025. PMC 3772115. PMID 24069563.
- ↑ 2.0 2.1 2.2 2.3 Vannucchi AM (2017). "From leeches to personalized medicine: evolving concepts in the management of polycythemia vera". Haematologica. 102 (1): 18–29. doi:10.3324/haematol.2015.129155. PMC 5210229. PMID 27884974.